Increase in the apoptotic molecule Fas ligand (FasL) in serum and cardiomyocytes has been shown to be associated with progressive dilated cardiomyopathy (DCM) and congestive heart failure (CHF) in humans. However, the underlying mechanism(s) of FasL-related deterioration of heart function remain obscure. The aim of the present study is to determine roles of myocardial FasL in the activation of alternative pathways such as extracellular-signal-regulated kinase 1/2 (ERK1/2), inflammation or fibrosis and to identify effective treatments of progressive DCM and advanced CHF. Transgenic mice with cardiomyocyte-specific overexpression of FasL were investigated and treated with an ERK1/2 inhibitor (U-0126), losartan (los), prednisolone (pred) or placebo. Morpho-histological and molecular studies were subsequently performed. FasL mice showed significantly higher mortality compared with wild-type (WT) littermates due to DCM and advanced CHF. Prominent perivascular and interstitial fibrosis, increased interleukin secretion and diffuse CD3-positive cell infiltration were evident in FasL hearts. Up-regulation of the short form of Fas-associated death domain (FADD)-like interleukin 1β-converting enzyme (FLICE) inhibitory protein (s-FLIP), RIP (receptor-interacting protein) and ERK1/2 and down-regulation of transforming growth factor beta 1 (TGFβ1) and nuclear factor-κB (NF-κB) was determined in the myocardium, whereas expression of ERK1/2, periostin (Postn) and osteopontin increased in cardiac fibroblasts. U-0126 and los increased CHF survival by 75% compared with pred and placebo groups. U-0126 had both anti-fibrotic and anti-apoptotic effects, whereas los reduced fibrosis only. Myocardial FasL expression in mice activates differential robust fibrotic, apoptotic and inflammatory responses via ERK1/2 in cardiomyocytes and cardiac fibroblasts inducing DCM and CHF. Blocking the ERK1/2 pathway prevented progression of FasL-induced DCM and CHF by reducing fibrosis, inflammation and apoptosis in the myocardium.
Skip Nav Destination
Article navigation
February 2016
-
Cover Image
Cover Image
Image modified from a figure representing the 5 mechanisms of annexin A1 externalization through non-classic secretory pathways, discussed by Boudhraa et al in issue 130(4) of Clinical Science. For further details please see pp. 205–220. Image kindly provided by Z. Boudhraa, B. Bouchon, C. Viallard, M. D'Incan and F. Degoul.Close Modal
Research Article|
January 14 2016
FasL expression in cardiomyocytes activates the ERK1/2 pathway, leading to dilated cardiomyopathy and advanced heart failure
Anne-Cecile Huby;
Anne-Cecile Huby
*Texas Heart Institute, Regenerative Medicine Research, Houston, TX 77030, U.S.A.
†Department of Pediatrics, The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, U.S.A.
Search for other works by this author on:
Subat Turdi;
Subat Turdi
†Department of Pediatrics, The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, U.S.A.
‡Department of Pediatrics, The Heart Institute, University of Tennessee Health Science Center, Memphis, TN 38103, U.S.A.
Search for other works by this author on:
Jeanne James;
Jeanne James
†Department of Pediatrics, The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, U.S.A.
Search for other works by this author on:
Jeffrey A. Towbin;
Jeffrey A. Towbin
†Department of Pediatrics, The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, U.S.A.
‡Department of Pediatrics, The Heart Institute, University of Tennessee Health Science Center, Memphis, TN 38103, U.S.A.
Search for other works by this author on:
Enkhsaikhan Purevjav
†Department of Pediatrics, The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, U.S.A.
‡Department of Pediatrics, The Heart Institute, University of Tennessee Health Science Center, Memphis, TN 38103, U.S.A.
Correspondence: Dr Enkhsaikhan Purevjav (email epurevjav@uthsc.edu).
Search for other works by this author on:
Clin Sci (Lond) (2016) 130 (4): 289–299.
Article history
Received:
September 03 2015
Revision Received:
October 30 2015
Accepted:
November 13 2015
Accepted Manuscript online:
November 13 2015
Citation
Anne-Cecile Huby, Subat Turdi, Jeanne James, Jeffrey A. Towbin, Enkhsaikhan Purevjav; FasL expression in cardiomyocytes activates the ERK1/2 pathway, leading to dilated cardiomyopathy and advanced heart failure. Clin Sci (Lond) 1 February 2016; 130 (4): 289–299. doi: https://doi.org/10.1042/CS20150624
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.